ExoCoBio Inc. initiated its “Project EGMP with the construction of the world’s first exosome-based drug manufacturing and R&D facility in Osong, Chungcheongbuk-do, South Korea. Osong serves as a bio-cluster to attract biotechnology businesses with government agencies like Korea FDA.
 
ExoCoBio will invest approximately $20 million to build the EGMP facility. After two years of preparation, its construction began in August this year.
 
This EGMP facility, a two-story building with 21,000 sq. ft. per story is expected to become a world-class facility of innovative exosome-based new drugs.
 
The EGMP facility will have installed two types of advanced exosome production lines, not only for naïve stem cell exosomes of regenerative medicine, but also for genetically engineered exosomes as a new future therapeutic portfolio, both of which have been continuously developed by ExoCoBio. The EGMP facility is expected to be completed by the end of 2022.
 
ExoCoBio aims to apply for phase 1 clinical trials in the U.S. in 2023 and it’s expected to gain strong momentum for the development of a variety of exosome-based therapeutics against inflammatory diseases such as atopic dermatitis, SARS-CoV-2, Dupilumab Facial Redness (DFR), and others. ExoCoBio currently sells its exosome products in the U.S. through its long-term partner and exclusive distributor, BENEV Company Inc., a California based FDA-approved manufacturer and distributor of skincare and regenerative solution products and medical devices.
 
ExoCoBio will continue to broaden its presence in the regenerative aesthetics and exosome-based therapeutic markets in North and South America in conjunction with BENEV.
 
Additionally, ExoCoBio plans to promote exosome CDMO business through partnering with global exosome researchers and companies who require large scale exosome production.